{"id":32552,"date":"2025-02-18T09:03:47","date_gmt":"2025-02-18T08:03:47","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=32552"},"modified":"2025-02-18T10:46:39","modified_gmt":"2025-02-18T09:46:39","slug":"hero-rekrutierung","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/de\/hero-rekrutierung\/","title":{"rendered":"Startschuss der Rekrutierung f\u00fcr HERO: CRISPR cas13-Studie f\u00fcr MDS"},"content":{"rendered":"<p><strong>Die HERO-Studie ist eine wegweisende klinische Untersuchung zur Bewertung von HG204, einer neuartigen CRISPR-Cas13-RNA-Editierungstherapie f\u00fcr das MECP2-Duplikationssyndrom (MDS). Gesponsert von HuidaGene, stellt diese Studie einen bedeutenden Fortschritt in der Suche nach einer Behandlung f\u00fcr MDS dar. Im November 2024 wurde der erste Patient erfolgreich mit HG204 behandelt \u2013 ein Meilenstein, der der MDS-Community neue Hoffnung gibt.  <\/strong> <\/p>\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-fill\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/dupmecp2.eu\/de\/crispr-cas13-une-technologie-revolutionnaire-a-haut-potentiel\/?lang=fr\" style=\"border-radius:10px;background-color:#f7a13f\" target=\"_blank\" rel=\"noreferrer noopener\">Mehr \u00fcber die Technologie<\/a><\/div>\n<\/div>\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>Studien\u00fcberblick<\/strong> <\/p>\n\n<p>Die HERO-Studie umfasst eine einmalige Injektion von HG204 mittels intrazerebroventrikul\u00e4rer Verabreichung, bei der die Therapie direkt ins Gehirn gelangt. Die Rekrutierung der Teilnehmer begann im Oktober 2024. Ziel ist die Aufnahme von sechs m\u00e4nnlichen Teilnehmern im Alter von 2 bis 18 Jahren mit gesicherter MECP2-Duplikationssyndrom-Diagnose.\nJeder Teilnehmer nimmt an der 60-w\u00f6chigen Studie teil, die sich in folgende Phasen gliedert:\n\u00b7 8-w\u00f6chige Screening-Phase\n\u00b7 Behandlung mit HG204\n\u00b7 52-w\u00f6chige Nachbeobachtung\nDie prim\u00e4ren Ziele der Studie sind die \u00dcberwachung von unerw\u00fcnschten Ereignissen sowie die Beurteilung des entwicklungsbezogenen Fortschritts nach der Behandlung.\nDerzeit wird die Studie am Peking University Hospital in Peking, China, durchgef\u00fchrt. Eine weitere Patientenrekrutierung in China h\u00e4ngt von den Ergebnissen der ersten behandelten Teilnehmer ab.      <\/p>\n\n<p>F\u00fcr detailliertere Informationen laden wir Sie ein, das Studienprotokoll zu lesen.<\/p>\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-fill\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06615206?cond=Mecp2DuplicationSyndrome&amp;rank=1\" style=\"border-radius:10px;background-color:#f7a13f\" target=\"_blank\" rel=\"noreferrer noopener\">Zum Studienprotokoll<\/a><\/div>\n<\/div>\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>Erster Patient behandelt &amp; erste Ergebnisse<\/strong> <\/p>\n\n<p>Im November gab HuidaGene die erfolgreiche Verabreichung von HG204 an den ersten Patienten bekannt. Sechs Wochen nach der Injektion traten keine schwerwiegenden Nebenwirkungen auf, und es wurden erste positive Anzeichen f\u00fcr die Wirksamkeit der Therapie beobachtet.\nIn den kommenden Wochen wird der Patient weiterhin engmaschig \u00fcberwacht, um die Sicherheit und Wirksamkeit der Behandlung weiter zu evaluieren.   <\/p>\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>N\u00e4chste Schritte &amp; Ziele<\/strong> <\/p>\n\n<p>HuidaGene hat wichtige Fortschritte bei den regulatorischen Genehmigungen erzielt und f\u00fcr HG204 zwei bedeutende FDA-Designationen erhalten:\n\u00b7 Rare Pediatric Disease Designation (RPDD)\n\u00b7 Orphan Drug Designation (ODD)\nDiese Auszeichnungen best\u00e4tigen das Potenzial von HG204 zur Behandlung des MECP2-Duplikationssyndroms. W\u00e4hrend die HERO-Studie in China durchgef\u00fchrt wird, hat das Biotech-Unternehmen bereits Gespr\u00e4che mit der FDA und der EMA aufgenommen, um m\u00f6gliche weitere Studien in den USA und Europa zu pr\u00fcfen.  <\/p>\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>Ver\u00f6ffentlichte Studien<\/strong> <\/p>\n\n<p>In der Zwischenzeit hat HuidaGene in Nature Neuroscience Einzelheiten zu vorklinischen experimentellen Erkenntnissen \u00fcber die CRISPR-Cas13-Technologie, einschlie\u00dflich HG204, ver\u00f6ffentlicht. <em>CRISPR-Cas13, <\/em>Die Studien haben gezeigt, dass HG204 die MECP2-mRNA-Spiegel wirksam senkt, die Krankheitssymptome lindert und die Lebensspanne in M\u00e4usen und nicht-menschlichen Primatenmodellen verl\u00e4ngert, ohne negative Auswirkungen zu verursachen. Diese Ergebnisse st\u00e4rken das Vertrauen in die laufende klinische Studie und das Potenzial von HG204 als therapeutische Option f\u00fcr MDS.   <\/p>\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-fill\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/www.nature.com\/articles\/s41593-024-01838-6\" style=\"border-radius:10px;background-color:#f7a13f\" target=\"_blank\" rel=\"noreferrer noopener\">Zur Publikation<\/a><\/div>\n<\/div>\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Die HERO-Studie stellt einen bedeutenden Fortschritt in der Suche nach einer Behandlung f\u00fcr das MECP2-Duplikationssyndrom dar. Die Kombination aus hochmoderner CRISPR-Cas13-Technologie und den ersten vielversprechenden Ergebnissen gibt betroffenen Patienten und Familien neue Hoffnung.\nIn den kommenden Monaten wird die fortlaufende \u00dcberwachung und Forschung entscheidend sein, um die Sicherheit und Wirksamkeit von HG204 bei der Behandlung von MDS umfassend zu bewerten.   <\/p>\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>L&rsquo;essai clinique HERO est une \u00e9tude pionni\u00e8re \u00e9valuant le HG204, une nouvelle th\u00e9rapie CRISPR Cas13 d&rsquo;\u00e9dition de l&rsquo;ARN, pour le syndrome de duplication MECP2 (MDS). Sponsoris\u00e9 par HuidaGene, cet essai [&hellip;]<\/p>","protected":false},"author":1,"featured_media":32702,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-32552","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>D\u00e9but du recrutement pour l&#039;essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2<\/title>\n<meta name=\"description\" content=\"L&#039;essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d&#039;un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l&#039;espoir aux patients et aux familles touch\u00e9s par ce syndrome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/de\/hero-rekrutierung\/?lang=fr\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u00e9but du recrutement pour l&#039;essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"L&#039;essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d&#039;un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l&#039;espoir aux patients et aux familles touch\u00e9s par ce syndrome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/de\/hero-rekrutierung\/?lang=fr\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T08:03:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-18T09:46:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"6\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"D\u00e9but du recrutement pour l&rsquo;essai clinique HERO : CRISPR cas13 pour le syndrome\",\"datePublished\":\"2025-02-18T08:03:47+00:00\",\"dateModified\":\"2025-02-18T09:46:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\",\"url\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\",\"name\":\"D\u00e9but du recrutement pour l'essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"datePublished\":\"2025-02-18T08:03:47+00:00\",\"dateModified\":\"2025-02-18T09:46:39+00:00\",\"description\":\"L'essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d'un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l'espoir aux patients et aux familles touch\u00e9s par ce syndrome.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/dupmecp2.eu\/category\/news\/?lang=en\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"D\u00e9but du recrutement pour l&rsquo;essai clinique HERO : CRISPR cas13 pour le syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/de\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Beginn der Rekrutierung f\u00fcr die klinische Studie HERO: CRISPR cas13 f\u00fcr das Syndrom - DupMECP2","description":"Die klinische Studie HERO stellt einen wichtigen Schritt auf der Suche nach einer Behandlung f\u00fcr das MECP2-Genduplikationssyndrom dar. Die Kombination aus der hochmodernen CRISPR cas13 -Technologie und den vielversprechenden vorl\u00e4ufigen Ergebnissen gibt den von diesem Syndrom betroffenen Patienten und Familien Hoffnung.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/de\/hero-rekrutierung\/?lang=fr","og_locale":"de_DE","og_type":"article","og_title":"D\u00e9but du recrutement pour l'essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2","og_description":"L'essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d'un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l'espoir aux patients et aux familles touch\u00e9s par ce syndrome.","og_url":"https:\/\/dupmecp2.eu\/de\/hero-rekrutierung\/?lang=fr","og_site_name":"DupMECP2","article_published_time":"2025-02-18T08:03:47+00:00","article_modified_time":"2025-02-18T09:46:39+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Caroline","Gesch\u00e4tzte Lesezeit":"6\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"D\u00e9but du recrutement pour l&rsquo;essai clinique HERO : CRISPR cas13 pour le syndrome","datePublished":"2025-02-18T08:03:47+00:00","dateModified":"2025-02-18T09:46:39+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr"},"wordCount":586,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr","url":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr","name":"Beginn der Rekrutierung f\u00fcr die klinische Studie HERO: CRISPR cas13 f\u00fcr das Syndrom - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","datePublished":"2025-02-18T08:03:47+00:00","dateModified":"2025-02-18T09:46:39+00:00","description":"Die klinische Studie HERO stellt einen wichtigen Schritt auf der Suche nach einer Behandlung f\u00fcr das MECP2-Genduplikationssyndrom dar. Die Kombination aus der hochmodernen CRISPR cas13 -Technologie und den vielversprechenden vorl\u00e4ufigen Ergebnissen gibt den von diesem Syndrom betroffenen Patienten und Familien Hoffnung.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/dupmecp2.eu\/category\/news\/?lang=en"},{"@type":"ListItem","position":3,"name":"D\u00e9but du recrutement pour l&rsquo;essai clinique HERO : CRISPR cas13 pour le syndrome"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/de\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/32552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/comments?post=32552"}],"version-history":[{"count":12,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/32552\/revisions"}],"predecessor-version":[{"id":32746,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/32552\/revisions\/32746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/media\/32702"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/media?parent=32552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/categories?post=32552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/tags?post=32552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}